Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

INtravesical Phase 1/1b Study of STING Agonist E7766 in NMIBC Including Subjects Unresponsive to BCG Therapy, INPUT-102

NCT04109092 is registered in ClinicalTrials.gov with Eisai Inc. as lead sponsor.

NCT NCT04109092
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04109092 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
INtravesical Phase 1/1b Study of STING Agonist E7766 in NMIBC Including Subjects Unresponsive to BCG Therapy, INPUT-102
Lead sponsor
Eisai Inc.
Phase
Phase 1
Overall status
Withdrawn
Start date
February 13, 2020
Completion date
September 29, 2022
Enrollment
0 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

urinary bladder neoplasms